[go: up one dir, main page]

EA202092335A1 - Композиции на основе эренумаба и пути их применения - Google Patents

Композиции на основе эренумаба и пути их применения

Info

Publication number
EA202092335A1
EA202092335A1 EA202092335A EA202092335A EA202092335A1 EA 202092335 A1 EA202092335 A1 EA 202092335A1 EA 202092335 A EA202092335 A EA 202092335A EA 202092335 A EA202092335 A EA 202092335A EA 202092335 A1 EA202092335 A1 EA 202092335A1
Authority
EA
Eurasian Patent Office
Prior art keywords
erenumab
variants
ways
application
compositions based
Prior art date
Application number
EA202092335A
Other languages
English (en)
Inventor
Кеннет Лоусон
Ноэль Ридер
Суминда Хапуараччи
Хосе Грегорио Рамирес
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Publication of EA202092335A1 publication Critical patent/EA202092335A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/26—Conditioning of the fluid carrier; Flow patterns
    • G01N30/38—Flow patterns
    • G01N30/46—Flow patterns using more than one column
    • G01N30/461—Flow patterns using more than one column with serial coupling of separation columns
    • G01N30/463—Flow patterns using more than one column with serial coupling of separation columns for multidimensional chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к композициям, содержащим эренумаб и один или несколько вариантов эренумаба, включая изомеризованные варианты, дезамидированные варианты, кислые варианты и HMW-разновидности. Также описаны фармацевтические составы, содержащие композиции на основе эренумаба, и способы применения и определения характеристик композиций.
EA202092335A 2018-04-02 2019-04-01 Композиции на основе эренумаба и пути их применения EA202092335A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862651651P 2018-04-02 2018-04-02
PCT/US2019/025223 WO2019195185A1 (en) 2018-04-02 2019-04-01 Erenumab compositions and uses thereof

Publications (1)

Publication Number Publication Date
EA202092335A1 true EA202092335A1 (ru) 2021-01-22

Family

ID=66248665

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092335A EA202092335A1 (ru) 2018-04-02 2019-04-01 Композиции на основе эренумаба и пути их применения

Country Status (19)

Country Link
US (2) US11407838B2 (ru)
EP (1) EP3774881A1 (ru)
JP (2) JP2021519790A (ru)
KR (1) KR20200139720A (ru)
CN (1) CN111954678A (ru)
AR (1) AR114722A1 (ru)
AU (1) AU2019246983A1 (ru)
BR (1) BR112020019882A2 (ru)
CA (1) CA3095899A1 (ru)
CL (2) CL2020002519A1 (ru)
EA (1) EA202092335A1 (ru)
IL (1) IL277663A (ru)
MA (1) MA52202A (ru)
MX (1) MX2020010320A (ru)
PH (1) PH12020551618A1 (ru)
SA (1) SA520420261B1 (ru)
SG (1) SG11202009629YA (ru)
TW (1) TWI847980B (ru)
WO (1) WO2019195185A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2023120561A1 (ja) * 2021-12-22 2023-06-29 中外製薬株式会社 生物活性が低下した抗体バリアント

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
AU673347B2 (en) 1992-03-17 1996-11-07 Novartis Ag Genetically engineered antibodies
AU7953194A (en) 1994-08-16 1996-03-07 Human Genome Sciences, Inc. Calcitonin receptor
US5785682A (en) 1995-03-22 1998-07-28 Abbott Laboratories Pre-filled syringe drug delivery system
WO1998003534A1 (en) 1996-07-23 1998-01-29 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
CN1260249C (zh) 1998-05-06 2006-06-21 基因技术股份有限公司 用离子交换层析纯化蛋白质
JP2002517406A (ja) 1998-06-01 2002-06-18 ジェネンテック・インコーポレーテッド イオン交換クロマトグラフィーの使用による、凝集体からのタンパク質モノマーの分離
FR2821080B1 (fr) 2001-02-20 2003-12-19 Sanofi Synthelabo Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
ATE453661T1 (de) 2001-09-27 2010-01-15 Merck & Co Inc Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodieren, damit verwandte, nichthumane transgene tiere und assayverfahren
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
ATE423553T1 (de) 2002-08-12 2009-03-15 Actavis Group Hf Verwendung von cgrp-antagonisten-verbindungen zur behandlung von psoriasis
US20040176577A1 (en) 2002-09-10 2004-09-09 Eva Rojer Immunoassays for specific determination of SCCA isoforms
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
NZ579621A (en) 2004-02-11 2011-03-31 Amylin Pharmaceuticals Inc Hybrid polypeptides with selectable properties
WO2006060083A1 (en) 2004-10-22 2006-06-08 Amgen Inc. Methods for refolding polypeptides
WO2006047340A2 (en) 2004-10-22 2006-05-04 Amgen Inc. Methods for refolding of recombinant antibodies
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
RS52036B (en) 2004-12-21 2012-04-30 Medimmune Limited ANGIOPOETIN-2 ANTIBODIES AND ITS USES
US9072777B2 (en) 2005-06-16 2015-07-07 Takayuki Shindo Method for screening substance having proangiogenic effect
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
CN103421114B (zh) 2005-11-14 2017-09-22 莱布瑞斯生物公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
WO2007076336A1 (en) 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
RU2009107277A (ru) 2006-08-03 2010-09-10 Астразенека Аб (Se) АНТИТЕЛА, НАЦЕЛЕННЫЕ НА αVβ6, И ИХ ПРИМЕНЕНИЕ
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
BRPI0908276B8 (pt) 2008-03-04 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite
FR2934597B1 (fr) 2008-07-31 2013-04-19 Univ Aix Marseille Ii Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament.
CN107184976A (zh) * 2008-11-20 2017-09-22 弗·哈夫曼-拉罗切有限公司 治疗性蛋白质制剂
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
KR20110128333A (ko) * 2009-03-06 2011-11-29 제넨테크, 인크. 항체 제제
AU2010275774B2 (en) * 2009-07-24 2016-03-31 F. Hoffmann-La Roche Ag Optimizing the production of antibodies
CN102740884A (zh) 2009-08-28 2012-10-17 瑞纳神经科学公司 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法
ES2651065T3 (es) 2009-12-18 2018-01-24 Novartis Ag Solución de lavado y método para cromatografía de afinidad
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
RS66303B1 (sr) 2011-05-20 2025-01-31 H Lundbeck As Upotreba anti-cgrp antitela i fragmenata antitela za sprečavanje ili inhibiranje fotofobije ili odbojnosti prema svetlu kod subjekata kojima je to potrebno, naročito kod subjekata koji pate od migrene
US9783570B2 (en) 2011-07-01 2017-10-10 Hoffmann-La Roche Inc. Method for separation of monomeric polypeptides from aggregated polypeptides
US20140371427A1 (en) * 2011-12-07 2014-12-18 Amgen Inc. IgG2 DISULFIDE ISOFORM SEPARATION
EP2791176B1 (en) * 2011-12-15 2018-07-11 Prestige Biopharma Pte. Ltd. A method of antibody purification
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
CA2906737C (en) 2013-03-15 2023-08-15 Amgen Inc. Human pac1 antibodies
WO2015006686A1 (en) * 2013-07-12 2015-01-15 Genentech, Inc. Elucidation of ion exchange chromatography input optimization
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
KR102274964B1 (ko) 2014-03-21 2021-07-09 테바 파마슈티컬스 인터내셔널 게엠베하 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
TW201620938A (zh) 2014-09-15 2016-06-16 安美基公司 雙特異性抗cgrp受體/pac1受體抗原結合蛋白質及其用途
JOP20200116A1 (ar) * 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp

Also Published As

Publication number Publication date
US20190300617A1 (en) 2019-10-03
SA520420261B1 (ar) 2024-05-23
CL2023000491A1 (es) 2023-10-13
MX2020010320A (es) 2021-01-08
CN111954678A (zh) 2020-11-17
JP2023103323A (ja) 2023-07-26
TW202003572A (zh) 2020-01-16
SG11202009629YA (en) 2020-10-29
CL2020002519A1 (es) 2021-04-05
TWI847980B (zh) 2024-07-11
MA52202A (fr) 2021-02-17
BR112020019882A2 (pt) 2021-01-05
AU2019246983A1 (en) 2020-10-29
IL277663A (en) 2020-11-30
WO2019195185A1 (en) 2019-10-10
EP3774881A1 (en) 2021-02-17
US11407838B2 (en) 2022-08-09
PH12020551618A1 (en) 2021-08-16
KR20200139720A (ko) 2020-12-14
JP2021519790A (ja) 2021-08-12
US20220348673A1 (en) 2022-11-03
CA3095899A1 (en) 2019-10-10
AR114722A1 (es) 2020-10-07

Similar Documents

Publication Publication Date Title
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
EA202092586A1 (ru) Ингибиторы magl
EA201890052A1 (ru) Регуляторы nrf2
MX2021015761A (es) Polipeptidos.
EA201890247A1 (ru) Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин
EA201991799A1 (ru) Диспергируемые в воде составы
EA201991798A1 (ru) Стабильные при хранении составы
EA202191806A1 (ru) Антитело против человеческого il-4ra и его применение
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201892203A1 (ru) Оксабороловые сложные эфиры, их применение
EA201990998A1 (ru) Фармацевтические составы и способы их получения
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение
EA201790336A1 (ru) Антитела к ангиопоэтинподобному белку 4 и способы применения
EA201792262A1 (ru) Пироглутамат вортиоксетина
EA201992883A1 (ru) АНТИТЕЛА К TrkB
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
EA202090424A1 (ru) Бициклические ингибиторы гистондеацетилазы
EA202191403A1 (ru) Композиция с высокой концентрацией белка
EA202190217A1 (ru) Формы ивосидениба и фармацевтические композиции
EA202090971A1 (ru) Способы применения и композиции, содержащие дулаглутид
EA201892376A1 (ru) Комбинированный состав трех противовирусных соединений